Exciting new trials in metastatic breast cancer have led to changing standard of care for patients. The CDK 4/6 inhibitors are an obvious example in oestrogen receptor positive disease in combination with endocrine therapy. Whilst we hear a lot about immunotherapy, in Australia we are still waiting to be able to use this routinely (and in a funded manner) in a subset of patients that may benefit. The “new” kids on the block are the antibody drug conjugates (drugs like T-DM1) which have shown impressive survival benefits for patients in the advanced setting.
Dr Belinda Yeo
VCCC Alliance Research and Education Lead - breast cancer
Medical Oncologist, Austin Health
ASCENT - Conquering an uphill battle in advanced triple negative breast cancer?
Dr Iris Tung
Breast Cancer Fellow, Austin Health
DESTINY is changing the treatment landscape in HER2+ breast cancer – an update on T-DXd and other novel antiHER2 therapies
Dr Julia Dixon-Douglas
Breast Cancer Trials Research Fellow, Peter MacCallum Cancer Centre
Jim Siderov AM BPharm MClinPharm BCOP AdvPracPharm FSHP
Senior Pharmacist, Cancer Services
Austin Health
More to be announced
For further information on the program, please contact Jasper de Boer, VCCC Alliance Program Manager, Distributed Leadership [email protected]
This virtual event will be hosted via Zoom. Zoom is accessible on your computer, tablet or phone via the Zoom app. If you have any issues with this platform on your device, please visit the Zoom support site. Alternatively please contact your IT administrator.
